Id leukemia: diagnosis and remedy. Mayo Clin Proc, 2006; 81: 9738 two. Druker BJ, Lydon B: Lessons learned in the improvement of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest, 2000; 105: 3 three. Schenone S, Zanoli S, Brullo C et al: Existing Advances within the Improvement of Adenylate Cyclase manufacturer Anticancer Drugs Targeting Tyrosine Kinases from the Src Family. Present Drug Therapy, 2008; 3: 1586 4. Remsing Rix LL, Rix U, Colinge J et al: International target profile from the kinase inhibitor bosutinib in major chronic myeloid leukemia cells. Leukemia, 2009; 23: 4775 5. Cortes JE, Kantarjian HM, Brummendorf TH et al: Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia sufferers with resistance or intolerance to imatinib. Blood, 2011; 118: 45676 six. Berman E, Nicolaides M, Maki RG et al: Altered bone and mineral metabolism in individuals receiving imatinib mesylate. N Engl J Med, 2006; 354: 20063 7. Fitter S, Dewar AL, Kostakis P et al: Long-term imatinib therapy promotes bone formation in CML sufferers. Blood, 2008; 111: 25387 eight. Mariani S, Giona F, Basciani S et al: Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib in the course of puberty. Lancet, 2008; 372: 1112 9. Schmid H, J er B, Lohse J, Suttorp M: Longitudinal growth retardation in a prepupertal girl with chronic myeloid leukemia on long-term imatinib treatment. Haematologica, 2009; 94: 11779 10. Kimoto T, Inoue M, Kawa K: Growth deceleration inside a girl treated with imatinib. Int J Hematol, 2009; 89: 2512 11. Millot F, Baruchel A, Guilhot J et al: Imatinib is efficient but has a unfavorable influence on growth in young children with previously untreated chronic myelogenous leukaemia (CML) in early chronic phase (CP): results on the French national phase IV trial. (abstract) Blood, 2009; 114: 356 12. Dewar AL, Cambareri AC, Zannettino AC et al: Macrophage colony-stimulating issue receptor c-fms is actually a novel target of imatinib. Blood, 2005; 105: 31272 13. Knight B, Tirnitz-Parker JE, Olynyk JK: C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice. Gastroenterology, 2008; 135: 9699 14. Tibullo D, Barbagallo I, Giallongo C et al: Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors. Hematol Oncol, 2012; 30: 273 15. Puttini M, Coluccia AM, Boschelli F et al: In vitro and in vivo activity of SKI606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res, 2006; 66: 113142 16. Quintas-Cardama A, Kantarjian H, Cortes J: Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov, 2007; six: 8348 17. Pfizer Laboratories. Pharmacology/ Toxicology NDA Critique and Evaluation. Meals and Drug Administration (FDA) Center for Drug Evaluation and Investigation. NDA 2011 ID: 203341 Out there from: URL: http://accessdata.fda.gov/ drugsatfda_docs/nda/2012/203341Orig1s000PharmR.pdf 18. Tauer JT, K ig S, Hofbauer LC, Suttorp M: A rat model to predict αvβ8 drug alterations in bone development and metabolism in kids with CML on imatinib. Haematologica, 2011; 96: 28 (abstract) 19. Cortes JE, Kim DW, Kantarjian HM et al: Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: final results from the BELA trial. J Clin Oncol, 2012; 30: 34862 20. Tibullo D, Giallongo C, La CP et al: Effects of imatinib mesylate in osteoblastogenesis. Exp.
